<DOC>
	<DOCNO>NCT00474955</DOCNO>
	<brief_summary>This single arm study ass efficacy safety PEGASYS patient chronic hepatitis C end-stage renal disease , include patient hemodialysis . Patients receive PEGASYS dose 180 microgram weekly ; calculate glomerular filtration rate &lt; 15mL/min receive reduce dose 135 micrograms weekly . Following 48 week treatment 24 week period treatment-free follow-up . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Patients With Chronic Hepatitis C Chronic Renal Failure .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient , 1860 year age ; chronic hepatitis C ; chronic renal failure , include patient hemodialysis therapy ; detectable HCV RNA level ( &gt; 500IU/mL ) . concurrent active hepatitis A B ; history evidence medical condition associate chronic liver disease HCV ; history evidence decompensated liver disease ; therapy systemic antiviral , antineoplastic immunomodulatory treatment &lt; =6 month prior study ; acute renal failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>